SEARCH

SEARCH BY CITATION

References

  • 1
    Furst DE, Amato AA, Iorga SR, Gajria K, Fernandes AW. Epidemiology of adult idiopathic inflammatory myopathies in a U.S. managed care plan. Muscle Nerve 2012; 45:676683.
  • 2
    Martin N, Li CK, Wedderburn LR. Juvenile dermatomyositis: new insights and new treatment strategies. Ther Adv Musculoskelet Dis 2012; 4:4150.
  • 3
    Callen JP. Dermatomyositis. Lancet 2000; 355:5357.
  • 4
    Sato S, Kuwana M, Fujita T, Suzuki Y. Anti-CADM-140/MDA5 autoantibody titer correlates with disease activity and predicts disease outcome in patients with dermatomyositis and rapidly progressive interstitial lung disease. Mod Rheumatol 2013; 23:496502.
  • 5
    Zahr ZA, Baer AN. Malignancy in myositis. Curr Rheumatol Rep 2011; 13:208215.
  • 6
    Ghazi E, Sontheimer RD, Werth VP. The importance of including amyopathic dermatomyositis in the idiopathic inflammatory myositis spectrum. Clin Exp Rheumatol 2013; 31:128134.
  • 7
    Sun Y, Liu Y, Yan B, Shi G. Interstitial lung disease in clinically amyopathic dermatomyositis (CADM) patients: a retrospective study of 41 Chinese Han patients. Rheumatol Int 2013; 33:12951302.
  • 8
    Kissel JT, Mendell JR, Rammohan KW. Microvascular deposition of complement membrane attack complex in dermatomyositis. N Engl J Med 1986; 314:329334.
  • 9
    Dalakas MC, Hohlfeld R. Polymyositis and dermatomyositis. Lancet 2003; 362:971982.
  • 10
    Greenberg SA. Dermatomyositis and type 1 interferons. Curr Rheumatol Rep 2010; 12:198203.
  • 11
    Baechler EC, Bilgic H, Reed AM. Type I interferon pathway in adult and juvenile dermatomyositis. Arthritis Res Ther 2011; 13:249.
  • 12
    Schmidt J, Barthel K, Wrede A, Salajegheh M, Bahr M, Dalakas MC. Interrelation of inflammation and APP in sIBM: IL-1 beta induces accumulation of beta-amyloid in skeletal muscle. Brain 2008; 131:12281240.
  • 13
    Civatte M, Schleinitz N, Krammer P et al. Class I MHC detection as a diagnostic tool in noninformative muscle biopsies of patients suffering from dermatomyositis (DM). Neuropathol Appl Neurobiol 2003; 29:546552.
  • 14
    De Paepe B, Creus KK, De Bleecker JL. Role of cytokines and chemokines in idiopathic inflammatory myopathies. Curr Opin Rheumatol 2009; 21:610616.
  • 15
    Schmidt J, Dalakas MC. Pathomechanisms of inflammatory myopathies: recent advances and implications for diagnosis and therapies. Expert Opin Med Diagn 2010; 4:241250.
  • 16
    Magro CM, Dyrsen M, Kerns MJ. Cutaneous lesions of dermatomyositis with supervening fibrosis. J Cutan Pathol 2008; 35:3139.
  • 17
    Hausmann G, Herrero C, Cid MC, Casademont J, Lecha M, Mascaro JM. Immunopathologic study of skin lesions in dermatomyositis. J Am Acad Dermatol 1991; 25:225230.
  • 18
    Mascaro JM Jr, Hausmann G, Herrero C et al. Membrane attack complex deposits in cutaneous lesions of dermatomyositis. Arch Dermatol 1995; 131:13861392.
  • 19
    Mastaglia FL, Garlepp MJ, Phillips BA, Zilko PJ. Inflammatory myopathies: clinical, diagnostic and therapeutic aspects. Muscle Nerve 2003; 27:407425.
  • 20
    De Paepe B, Creus KK, De Bleecker JL. The tumor necrosis factor superfamily of cytokines in the inflammatory myopathies: potential targets for therapy. Clin Dev Immunol 2012; 2012:369432.
  • 21
    Choi YC, Dalakas MC. Expression of matrix metalloproteinases in the muscle of patients with inflammatory myopathies. Neurology 2000; 54:6571.
  • 22
    Das L, Blumbergs PC, Manavis J, Limaye VS. Major histocompatibility complex class I and II expression in idiopathic inflammatory myopathy. Appl Immunohistochem Mol Morphol 2013; doi: 10.1097/PAI.0b013e31827d7f16.
  • 23
    Karpati G, Pouliot Y, Carpenter S. Expression of immunoreactive major histocompatibility complex products in human skeletal muscles. Ann Neurol 1988; 23:6472.
  • 24
    Ellis E, Ann TJ, Lester S et al. Necrotizing myopathy: clinicoserologic associations. Muscle Nerve 2012; 45:189194.
  • 25
    Miller T, Al-Lozi MT, Lopate G, Pestronk A. Myopathy with antibodies to the signal recognition particle: clinical and pathological features. J Neurol Neurosurg Psychiatry 2002; 73:420428.
  • 26
    Stenzel W, Goebel HH, Aronica E. Immune-mediated necrotizing myopathies – a heterogeneous group of diseases with specific myopathological features [Review]. Neuropathol Appl Neurobiol 2012; 38:632646.
  • 27
    Preusse C, Goebel HH, Held J et al. Immune-mediated necrotizing myopathy is characterized by a specific Th1-M1 polarized immune profile. Am J Pathol 2012; 181:21612171.
  • 28
    Hengstman GJ, ter Laak HJ, Vree Egberts WT et al. Anti-signal recognition particle autoantibodies: marker of a necrotising myopathy. Ann Rheum Dis 2006; 65:16351638.
  • 29
    Mammen AL, Chung T, Christopher-Stine L et al. Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy. Arthritis Rheum 2011; 63:713721.
  • 30
    Benveniste O, Drouot L, Jouen F et al. Correlation of anti-signal recognition particle autoantibody levels with creatine kinase activity in patients with necrotizing myopathy. Arthritis Rheum 2011; 63:19611971.
  • 31
    Liang C, Needham M. Necrotizing autoimmune myopathy. Curr Opin Rheumatol 2011; 23:612619.
  • 32
    Bronner IM, Hoogendijk JE, Wintzen AR et al. Necrotising myopathy, an unusual presentation of a steroid-responsive myopathy. J Neurol 2003; 250:480485.
  • 33
    Mastaglia FL, Needham M. Update on toxic myopathies. Curr Neurol Neurosci Rep 2012; 12:5461.
  • 34
    Needham M, Corbett A, Day T, Christiansen F, Fabian V, Mastaglia FL. Prevalence of sporadic inclusion body myositis and factors contributing to delayed diagnosis. J Clin Neurosci 2008; 15:13501353.
  • 35
    Cox FM, Titulaer MJ, Sont JK, Wintzen AR, Verschuuren JJ, Badrising UA. A 12-year follow-up in sporadic inclusion body myositis: an end stage with major disabilities. Brain 2011; 134:31673175.
  • 36
    Benveniste O, Guiguet M, Freebody J et al. Long-term observational study of sporadic inclusion body myositis. Brain 2011; 134:31763184.
  • 37
    Cox FM, Verschuuren JJ, Verbist BM, Niks EH, Wintzen AR, Badrising UA. Detecting dysphagia in inclusion body myositis. J Neurol 2009; 256:20092013.
  • 38
    Griggs RC, Askanas V, DiMauro S et al. Inclusion body myositis and myopathies. Ann Neurol 1995; 38:705713.
  • 39
    Badrising UA, Maat-Schieman M, van Duinen SG et al. Epidemiology of inclusion body myositis in the Netherlands: a nationwide study. Neurology 2000; 55:13851387.
  • 40
    Hilton-Jones D, Miller A, Parton M, Holton J, Sewry C, Hanna MG. Inclusion body myositis: MRC Centre for Neuromuscular Diseases, IBM workshop, London, 13 June 2008. Neuromuscul Disord 2010; 20:142147.
  • 41
    Askanas V, Engel WK, Nogalska A. Pathogenic considerations in sporadic inclusion-body myositis, a degenerative muscle disease associated with aging and abnormalities of myoproteostasis. J Neuropathol Exp Neurol 2012; 71:680693.
  • 42
    Muth IE, Barthel K, Bahr M, Dalakas MC, Schmidt J. Proinflammatory cell stress in sporadic inclusion body myositis muscle: overexpression of alphaB-crystallin is associated with amyloid precursor protein and accumulation of beta-amyloid. J Neurol Neurosurg Psychiatry 2009; 80:13441349.
  • 43
    Schmidt J, Barthel K, Zschuntzsch J et al. Nitric oxide stress in sporadic inclusion body myositis muscle fibres: inhibition of inducible nitric oxide synthase prevents interleukin-1beta-induced accumulation of beta-amyloid and cell death. Brain 2012; 135:11021114.
  • 44
    Lunemann JD, Schmidt J, Schmid D et al. Beta-amyloid is a substrate of autophagy in sporadic inclusion body myositis. Ann Neurol 2007; 61:476483.
  • 45
    Keller CW, Fokken C, Turville SG et al. TNF-alpha induces macroautophagy and regulates MHC class II expression in human skeletal muscle cells. J Biol Chem 2011; 286:39703980.
  • 46
    Keller CW, Schmitz M, Munz C, Lunemann JD, Schmidt J. TNF-alpha upregulates macroautophagic processing of APP/beta-amyloid in a human rhabdomyosarcoma cell line. J Neurol Sci 2013; 325:103107.
  • 47
    Fraser CL, Skalicky SE, Gurbaxani A, McCluskey P. Ocular myositis. Curr Allergy Asthma Rep 2013; 13:315321.
  • 48
    Laccarino L, Gatto M, Bettio S et al. Overlap connective tissue disease syndromes. Autoimmun Rev 2013; 12:363373.
  • 49
    Romans B, Cohen S. A rheumatologist's view of polymyositis/dermatomyositis: extracutaneous and extramuscular involvement and overlap syndromes. Clin Dermatol 1988; 6:1522.
  • 50
    Venables PJ. Polymyositis-associated overlap syndromes. Br J Rheumatol 1996; 35:305306.
  • 51
    Mimori T, Nakashima R, Hosono Y. Interstitial lung disease in myositis: clinical subsets, biomarkers, and treatment. Curr Rheumatol Rep 2012; 14:264274.
  • 52
    Gunawardena H, Betteridge ZE, McHugh NJ. Myositis-specific autoantibodies: their clinical and pathogenic significance in disease expression. Rheumatology (Oxf) 2009; 48:607612.
  • 53
    Richards TJ, Eggebeen A, Gibson K et al. Characterization and peripheral blood biomarker assessment of anti-Jo-1 antibody-positive interstitial lung disease. Arthritis Rheum 2009; 60:21832192.
  • 54
    Hamaguchi Y, Kuwana M, Hoshino K et al. Clinical correlations with dermatomyositis-specific autoantibodies in adult Japanese patients with dermatomyositis: a multicenter cross-sectional study. Arch Dermatol 2011; 147:391398.
  • 55
    Casciola-Rosen L, Mammen AL. Myositis autoantibodies. Curr Opin Rheumatol 2012; 24:602608.
  • 56
    Gunawardena H, Betteridge ZE, McHugh NJ. Newly identified autoantibodies: relationship to idiopathic inflammatory myopathy subsets and pathogenesis. Curr Opin Rheumatol 2008; 20:675680.
  • 57
    Salajegheh M, Lam T, Greenberg SA. Autoantibodies against a 43 KDa muscle protein in inclusion body myositis. PloS One 2011; 6:e20266.
  • 58
    Ray A, Amato AA, Bradshaw EM et al. Autoantibodies produced at the site of tissue damage provide evidence of humoral autoimmunity in inclusion body myositis. PLOS One 2012; 7:e46709.
  • 59
    Larman HB, Salajegheh M, Nazareno R et al. Cytosolic 5′-nucleotidase 1A autoimmunity in sporadic inclusion body myositis. Ann Neurol 2013; 73:408418.
  • 60
    Pluk H, van Hoeve BJ, van Dooren SH et al. Autoantibodies to cytosolic 5′-nucleotidase 1A in inclusion body myositis. Ann Neurol 2013; 73:397407.
  • 61
    Danko K, Ponyi A, Molnar AP, Andras C, Constantin T. Paraneoplastic myopathy. Curr Opin Rheumatol 2009; 21:594598.
  • 62
    Wegener S, Bremer J, Komminoth P, Jung HH, Weller M. Paraneoplastic necrotizing myopathy with a mild inflammatory component: a case report and review of the literature. Case Rep Oncol 2010; 3:8892.
  • 63
    Bazzani C, Cavazzana I, Ceribelli A, Vizzardi E, Dei CL, Franceschini F. Cardiological features in idiopathic inflammatory myopathies. J Cardiovasc Med (Hagerstown) 2010; 11:906911.
  • 64
    Blijham PJ, Hengstman GJ, Hama-Amin AD, van Engelen BG, Zwarts MJ. Needle electromyographic findings in 98 patients with myositis. Eur Neurol 2006; 55:183188.
  • 65
    Curiel RV, Jones R, Brindle K. Magnetic resonance imaging of the idiopathic inflammatory myopathies: structural and clinical aspects. Ann NY Acad Sci 2009; 1154:101114.
  • 66
    Winklehner A, Berger N, Maurer B, Distler O, Alkadhi H, Frauenfelder T. Screening for interstitial lung disease in systemic sclerosis: the diagnostic accuracy of HRCT image series with high increment and reduced number of slices. Ann Rheum Dis 2012; 71:549552.
  • 67
    Pereira RM, Carvalho JF, Paula AP et al. Guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis. Rev Bras Reumatol 2012; 52:580593.
  • 68
    Ertekin C, Secil Y, Yuceyar N, Aydogdu I. Oropharyngeal dysphagia in polymyositis/dermatomyositis. Clin Neurol Neurosurg 2004; 107:3237.
  • 69
    Mulcahy KP, Langdon PC, Mastaglia F. Dysphagia in inflammatory myopathy: self-report, incidence, and prevalence. Dysphagia 2012; 27:6469.
  • 70
    Langmore SE. Evaluation of oropharyngeal dysphagia: which diagnostic tool is superior? Curr Opin Otolaryngol Head Neck Surg 2003; 11:485489.
  • 71
    Micks RH, Mullaney J. Dermatomyositis successfully treated by prednisone. Ir J Med Sci 1958; 33:333334.
  • 72
    van de Vlekkert J, Hoogendijk JE, de Haan RJ et al. Oral dexamethasone pulse therapy versus daily prednisolone in sub-acute onset myositis, a randomised clinical trial. Neuromuscul Disord 2010; 20:382389.
  • 73
    Batchelor TT, Taylor LP, Thaler HT, Posner JB, DeAngelis LM. Steroid myopathy in cancer patients. Neurology 1997; 48:12341238.
  • 74
    Gordon PA, Winer JB, Hoogendijk JE, Choy EH. Immunosuppressant and immunomodulatory treatment for dermatomyositis and polymyositis. Cochrane Database Syst Rev 2012; (8)CD003643.
  • 75
    Levitt M, Mosher MB, DeConti RC et al. Improved therapeutic index of methotrexate with ‘leucovorin rescue’. Cancer Res 1973; 33:17291734.
  • 76
    Nydegger UE. Safety and side effects of i.v. immunoglobulin therapy. Clin Exp Rheumatol 1996; 14 (Suppl. 15):S53S57.
  • 77
    Lidar M, Langevitz P. Pregnancy issues in scleroderma. Autoimmun Rev 2012; 11:A515A519.
  • 78
    Makol A, Wright K, Amin S. Rheumatoid arthritis and pregnancy: safety considerations in pharmacological management. Drugs 2011; 71:19731987.
  • 79
    Ostensen M, Forger F. Management of RA medications in pregnant patients. Nat Rev Rheumatol 2009; 5:382390.
  • 80
    Oddis CV, Reed AM, Aggarwal R et al. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum 2013; 65:314324.
  • 81
    Levine TD. Rituximab in the treatment of dermatomyositis: an open-label pilot study. Arthritis Rheum 2005; 52:601607.
  • 82
    Mahler EA, Blom M, Voermans NC, van Engelen BG, van Riel PL, Vonk MC. Rituximab treatment in patients with refractory inflammatory myopathies. Rheumatology (Oxf) 2011; 50:22062213.
  • 83
    Muscle Study Group. A randomized, pilot trial of etanercept in dermatomyositis. Ann Neurol 2011; 70:427436.
  • 84
    Alexanderson H, Lundberg IE. Exercise as a therapeutic modality in patients with idiopathic inflammatory myopathies. Curr Opin Rheumatol 2012; 24:201207.
  • 85
    Lotz BP, Engel AG, Nishino H, Stevens JC, Litchy WJ. Inclusion body myositis. Observations in 40 patients. Brain 1989; 112:727747.
  • 86
    Lindberg C, Trysberg E, Tarkowski A, Oldfors A. Anti-T-lymphocyte globulin treatment in inclusion body myositis: a randomized pilot study. Neurology 2003; 61:260262.
  • 87
    Barohn RJ, Herbelin L, Kissel JT et al. Pilot trial of etanercept in the treatment of inclusion-body myositis. Neurology 2006; 66:S123S124.
  • 88
    Rutkove SB, Parker RA, Nardin RA, Connolly CE, Felice KJ, Raynor EM. A pilot randomized trial of oxandrolone in inclusion body myositis. Neurology 2002; 58:10811087.
  • 89
    Muscle Study Group. Randomized pilot trial of betaINF1a (Avonex) in patients with inclusion body myositis. Neurology 2001; 57:15661570.
  • 90
    Muscle Study Group. Randomized pilot trial of high-dose betaINF-1a in patients with inclusion body myositis. Neurology 2004; 63:718720.
  • 91
    Badrising UA, Maat-Schieman ML, Ferrari MD et al. Comparison of weakness progression in inclusion body myositis during treatment with methotrexate or placebo. Ann Neurol 2002; 51:369372.
  • 92
    Dalakas MC, Rakocevic G, Schmidt J et al. Effect of alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis. Brain 2009; 132:15361544.
  • 93
    Amato AA, Barohn RJ, Jackson CE, Pappert EJ, Sahenk Z, Kissel JT. Inclusion body myositis: treatment with intravenous immunoglobulin. Neurology 1994; 44:15161518.
  • 94
    Dalakas MC, Sonies B, Dambrosia J, Sekul E, Cupler E, Sivakumar K. Treatment of inclusion-body myositis with IVIg: a double-blind, placebo-controlled study. Neurology 1997; 48:712716.
  • 95
    Dalakas MC, Koffman B, Fujii M, Spector S, Sivakumar K, Cupler E. A controlled study of intravenous immunoglobulin combined with prednisone in the treatment of IBM. Neurology 2001; 56:323327.
  • 96
    Walter MC, Lochmuller H, Toepfer M et al. High-dose immunoglobulin therapy in sporadic inclusion body myositis: a double-blind, placebo-controlled study. J Neurol 2000; 247:2228.
  • 97
    Cherin P, Pelletier S, Teixeira A et al. Intravenous immunoglobulin for dysphagia of inclusion body myositis. Neurology 2002; 58:326327.
  • 98
    Murata KY, Kouda K, Tajima F, Kondo T. Balloon dilation in sporadic inclusion body myositis patients with dysphagia. Clin Med Insights Case Rep 2013; 6:17.
  • 99
    Sancricca C, Mora M, Ricci E, Tonali PA, Mantegazza R, Mirabella M. Pilot trial of simvastatin in the treatment of sporadic inclusion-body myositis. Neurol Sci 2011; 32:841847.
  • 100
    Phukan J. Arimoclomol, a coinducer of heat shock proteins for the potential treatment of amyotrophic lateral sclerosis. IDrugs 2010; 13:482496.
  • 101
    Ney DM, Weiss JM, Kind AJ, Robbins J. Senescent swallowing: impact, strategies, and interventions. Nutr Clin Pract 2009; 24:395413.
  • 102
    Marie I, Menard JF, Hatron PY et al. Intravenous immunoglobulins for steroid-refractory esophageal involvement related to polymyositis and dermatomyositis: a series of 73 patients. Arthritis Care Res (Hoboken) 2010; 62:17481755.
  • 103
    Oh TH, Brumfield KA, Hoskin TL, Stolp KA, Murray JA, Bassford JR. Dysphagia in inflammatory myopathy: clinical characteristics, treatment strategies, and outcome in 62 patients. Mayo Clin Proc 2007; 82:441447.
  • 104
    Oh TH, Brumfield KA, Hoskin TL, Kasperbauer JL, Basford JR. Dysphagia in inclusion body myositis: clinical features, management, and clinical outcome. Am J Phys Med Rehabil 2008; 87:883889.
  • 105
    Liu LW, Tarnopolsky M, Armstrong D. Injection of botulinum toxin A to the upper esophageal sphincter for oropharyngeal dysphagia in two patients with inclusion body myositis. Can J Gastroenterol 2004; 18:397399.
  • 106
    Kitamura T, Nakase H, Iizuka H. Risk factors for aspiration pneumonia after percutaneous endoscopic gastrostomy. Gerontology 2007; 53:224227.
  • 107
    Nagano H, Yoshifuku K, Kurono Y. Polymyositis with dysphagia treated with endoscopic balloon dilatation. Auris Nasus Larynx 2009; 36:705708.
  • 108
    Langdon PC, Mulcahy K, Shepherd KL, Low VH, Mastaglia FL. Pharyngeal dysphagia in inflammatory muscle diseases resulting from impaired suprahyoid musculature. Dysphagia 2012; 27:408417.
  • 109
    Schmidt J, Vorgerd M. Standard treatment for myositis and muscular dystrophies. Nervenarzt 2011; 82:723732.